Immune Alterations in Patients Treated With Everolimus for Metastatic Renal Cell Cancer
Abstract Background: The mammalian target of rapamycin (mTOR) is a key protein kinase present in all cells. As mTOR is an important regulator of cell growth, proliferation, angiogenesis, and survival of malignant tumors, mTOR inhibitors such as everolimus were studied and registered for the treatment of several types of cancer including metastatic renal cell … Read more